- Hepatitis B treatments and diagnostics are increasingly vital components of North America’s public health infrastructure, especially in both hospital and outpatient settings, due to rising infection awareness, improved testing accessibility, and advancements in antiviral therapies
- The escalating demand for effective Hepatitis B management is primarily fueled by widespread immunization efforts, increased HBV-HDV co-infection screening, and the rising burden of chronic liver diseases—particularly among aging populations and immigrant communities
- U.S. dominated the North America hepatitis B infection market with the largest revenue share of 57.9% in 2024, characterized by strong public health policies, the early adoption of advanced diagnostic technologies, and high HBV testing rates. The country has also witnessed significant growth in treatment uptake, especially among high-risk groups, fueled by public awareness campaigns, state-level elimination plans, and expanded insurance coverage for hepatitis care
- Mexico is expected to be the fastest-growing country within the North America hepatitis B infection market during the forecast period, supported by increasing urbanization, improved vaccination coverage, expanding government funding for hepatitis elimination, and enhanced access to healthcare services across both urban and rural areas
- The chronic hepatitis B segment dominated the North America hepatitis B infection market with a market share of 62.4% in 2024, owing to the persistent nature of the disease, the need for long-term antiviral therapy, and improved detection through targeted screening programs and integration of hepatitis testing into primary care
